Escolar Documentos
Profissional Documentos
Cultura Documentos
Paciente
Idade: 56 anos
Sexo: Feminino
Cidade: Mossoró/RN
Dados do Processo
Tecnologia 174601
Descrição da Tecnologia
Página 1 de 4
Tecnologia: 0406010633 - IMPLANTE DE MARCAPASSO CARDIACO MULTI-SITIO
TRANSVENOSO
Custo da Tecnologia
Custo da tecnologia: -
Conclusão
Página 2 de 4
diretrizes nacionais e internacionais de cardiodesfibrilador implantável em pacientes com
diagnóstico de miocardiopatia dilatada não isquêmica (chagásica), com FEVE < 30% e
presença de taquicardia ventricular não sustentada espontânea;
CONCLUI-SE que HÁ elementos técnicos suficientes para sustentar a indicação do
medicamento solicitado no presente caso, em regime de urgência.
Referências bibliográficas:
1. Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, Colafran
ceschi AS, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq.
Bras. Cardiol. 2018;111(3):436-59.
2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the
Management of Heart Failure: A Report of the American College of Cardiology/American
Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;
145:e895.
3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and
treatment of acute and chronic heart failure: The Task Force for the diagnosis and
treatment of acute and chronic heart failure of the European Society of Cardiology
(ESC)Developed with the special contribution of the Heart Failure Association (HFA) of
the ESC. Eur Heart J 2016; 37:2129.
4. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC Expert Consensus Decision
Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues
About Heart Failure With Reduced Ejection Fraction: A Report of the American College
of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol
2018; 71:201.
5. Marwick TH. The viable myocardium: epidemiology, detection, and clinical implications.
Lancet 1998; 351:815.
6. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and
impact of revascularization on prognosis in patients with coronary artery disease and left
ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.
7. Bortman G, Sellanes M, Odell DS, et al. Discrepancy between pre- and post-transplant
diagnosis of end-stage dilated cardiomyopathy. Am J Cardiol 1994; 74:921.
8. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation
and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart
J 2002; 144:524.
9. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as
supplementary vasodilator therapy in patients with chronic heart failure treated with
enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation
1997; 96:856.
10. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010
Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.
11. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA
guideline for the management of heart failure: a report of the American College of
Página 3 de 4
Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Circulation 2013; 128:e240.
12. Cooper LB, Hernandez AF. Assessing the Quality and Comparative Effectiveness of
Team-Based Care for Heart Failure: Who, What, Where, When, and How. Heart Fail
Clin 2015; 11:499.
13. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of
comprehensive disease-modifying pharmacological therapies in patients with heart
failure with reduced ejection fraction: a comparative analysis of three randomised
controlled trials. Lancet 2020; 396:121.
14. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in
patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet 2008; 372:1223.
15. Comitê Coordenador da Diretriz de Insuficiência Cardíaca. (2018). Diretriz brasileira de
insuficiência cardíaca crônica e aguda. Arquivos brasileiros de cardiologia, 111(3),
436-539.
Página 4 de 4